You have selected no: Nr.1/2017
Filter by:
ETHICAL IMPLICATIONS OF PLACEBO USING IN CLINICAL PRACTICE
Many authors consider that placebo history is in fact the history of medicine and this is probably true to a large extent. The placebo effect is still extremely used...
IMPLICATIONS OF THE INFLAMMATORY PROCESSES IN MAJOR DEPRESSIVE EPISODE
Abstract There are an increasing number of evidences that suggests that the immune system and inflammatory processes can contribute to MDD pathogenesis in a significant proportion. In this article,...
COGNITIVE IMPAIRMENT IN MAJOR DEPRESSIVE DISORDER
Cognitive impairment was considered for a long time to be part of depression and it was expected to disappear as other mood symptoms improved with treatment. Because of this...
THE IMPACT OF TREATMENT AND DURATION OF PSYCHOSIS ON RESIDUAL SYMPTOMS
Introduction: Literature data suggest that a longer duration of untreated psychosis or discontinuities in antipsychotic treatment impair...
C REACTIVE PROTEIN, A POSSIBLE BIOMARKER FOR THE MAJOR DEPRESSIVE EPISODE
The central nervous system has a bidirectional communication with the immune system by many mechanisms that could link depression with an increase of the inflammation markers like C reactive...
AMISULPRIDE – INDUCED HYPERPROLACTINEMIA- CASE REPORT
BACKGROUND: One of the most discussed adverse effect of antipsychotics is hyperprolactinemia. Dopamine antagonists block the D2 receptors of the lactotroph cells and prevent inhibition of...
